Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC).
Von Minckwitz G, O'Shaughnessy J, Winer E, Wolmark N, Geyer C, Huober J, Loibl S, Sikov W, Untch M, McKee M, Giranda V, Rugo H. Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC). Journal Of Clinical Oncology 2014, 32: tps1149-tps1149. DOI: 10.1200/jco.2014.32.15_suppl.tps1149.Peer-Reviewed Original Research